close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Werewolf Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Participate in May Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
News headline image
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today